Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pulmonary artery

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    291 result(s) found for: Pulmonary artery. Displaying page 5 of 15.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-004793-17 Sponsor Protocol Number: 402-C-1302 Start Date*: 2017-05-03
    Sponsor Name:Reata Pharmaceuticals, Inc.
    Full Title: A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension
    Medical condition: Pulmonary Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-016994-13 Sponsor Protocol Number: COU-001P Start Date*: 2010-03-19
    Sponsor Name:University Utrecht [...]
    1. University Utrecht
    2. Prof. Dr. R Marre, University Hospital Ulm
    3. Elisabethinen Hospital Linz
    Full Title: EUropean Pharmacogenetics of AntiCoagulation Therapy trial
    Medical condition: Newly diagnosed patients with venous tromboembolism (VTE) or atrial fibrillation (AF) requiring oral anticoagulation with phenprocoumon.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10003658 Atrial fibrillation LLT
    12.0 10012107 Deep venous thrombosis NOS LLT
    12.0 10037377 Pulmonary embolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002104-40 Sponsor Protocol Number: BAY63-2521/16097 Start Date*: 2013-03-14
    Sponsor Name:Bayer HealthCare AG
    Full Title: An open-label phase IIIb study of riociguat in patients with in-operable CTEPH, or recurrent or persisting PH after surgical treatment who are not satisfactorily treated and cannot participate in ...
    Medical condition: Chronic Trombo Embolic Pulmonary Hypertention
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10068740 CTEPH LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) PT (Completed) ES (Completed) BE (Completed) CZ (Completed) DK (Completed) NL (Completed) IT (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000072-16 Sponsor Protocol Number: BAY63-2521/11348 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic...
    Medical condition: Chronic Thromboembolic Pulmonary Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Prematurely Ended) GB (Completed) AT (Completed) ES (Completed) NL (Completed) FR (Completed) IT (Completed) BE (Completed) CZ (Completed) SK (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-005100-26 Sponsor Protocol Number: ORION-PH-1 Start Date*: 2017-10-09
    Sponsor Name:Hannover Medical School
    Full Title: A pilot Study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with pulmonary hypertension and iron deficiency an...
    Medical condition: Patients with iron deficiency anemia and pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022974 Iron deficiency anemia LLT
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000771-24 Sponsor Protocol Number: CXL-1427-02 Start Date*: 2014-12-22
    Sponsor Name:Cardioxyl Pharmaceuticals, Inc.
    Full Title: A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6-Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients with Systolic Heart Failure
    Medical condition: Heart failure with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10024106 Left heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003059-36 Sponsor Protocol Number: Bay 58-2667/12480 Start Date*: 2007-12-10
    Sponsor Name:Bayer Healthcare AG
    Full Title: Placebo controlled, randomized, double-blind, multi-center, multinational Phase IIb study to investigate the efficacy and tolerability of BAY 58-2667 given intravenously in patients with acute deco...
    Medical condition: Patients with acute decompensated chronic congested heart failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) SI (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005211-32 Sponsor Protocol Number: DS1040-B-U107 Start Date*: 2017-03-08
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of DS-1040b when Added to ...
    Medical condition: DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including Pulmonary Embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037379 Pulmonary embolism and thrombosis HLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004583-22 Sponsor Protocol Number: 548.12 Start Date*: 2012-10-20
    Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA
    Full Title: Verification of the effectiveness of intravenous sildenafil compared to other pulmonary vasodilators used in the test vessel reactivity of pulmonary
    Medical condition: Subjects in children with congenital heart disease surgery or not, with echocardiographic signs of pulmonary hypertension followed at the Pediatric Cardiology Centre of the Mediterranean or reporte...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10047065 Vascular disorders SOC
    Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002844-24 Sponsor Protocol Number: H6D-MC-LVGX Start Date*: 2006-04-10
    Sponsor Name:Lilly ICOS LLC
    Full Title: A Double-Blind, Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hyperte...
    Medical condition: Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterised by elevation of pulmonary artery pressure and pulmonary vascular resistance, leading to right heart failure ...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000804-18 Sponsor Protocol Number: TDE-PH-304 Start Date*: 2007-02-15
    Sponsor Name:United Therapeutics Corporation
    Full Title: An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension
    Medical condition: Idiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with : 1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037400 Pulmonary hypertension PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) NL (Completed) AT (Completed) FR (Completed) BE (Completed) IT (Completed) DE (Completed) SE (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000927-42 Sponsor Protocol Number: HZC116601 Start Date*: 2012-10-19
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation Effects of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg Once Da...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003093-27 Sponsor Protocol Number: GB002-1101 Start Date*: 2019-08-16
    Sponsor Name:GB002, Inc.
    Full Title: A Phase 1b, Randomized, Subject- and Investigator-Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biomarkers of Inhaled GB00...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077739 Pulmonary arterial hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-005885-30 Sponsor Protocol Number: B1321001 Start Date*: 2010-01-12
    Sponsor Name:Pfizer Ltd
    Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002354-23 Sponsor Protocol Number: H6D-MC-LVHV Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) IT (Prematurely Ended) AT (Completed) NL (Completed) PL (Completed) ES (Completed) RO (Ongoing) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-001464-23 Sponsor Protocol Number: A1481243 Start Date*: 2006-06-08
    Sponsor Name:Pfizer Ltd,Ramsgate Road,Sandwich CT13 9NJ
    Full Title: A multinational, multicentre, randomized, double-blind study to assess the efficacy and safety of oral sildenafil 20mg TID or placebo when added to Bosentan in the treatement of subjects , aged 18 ...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-002235-25 Sponsor Protocol Number: A1481131 Start Date*: 2006-12-14
    Sponsor Name:Pfizer Ltd, Ramsgate Rd, Sandwich, Kent, United Kingdom
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.0 10064911 LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FI (Prematurely Ended) SK (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000816-96 Sponsor Protocol Number: P160924 Start Date*: 2020-04-27
    Sponsor Name:AP-HP/ DRCI
    Full Title: A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism
    Medical condition: Intermediate high-risk acute pulmonary embolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) SI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004600-17 Sponsor Protocol Number: T21 Start Date*: Information not available in EudraCT
    Sponsor Name:Royal College of Surgeons in Ireland
    Full Title: The use of Sildenafil in Neonates with Down Syndrome to Reduce Pulmonary Vascular Resistance.
    Medical condition: to assess the impact of oral sildenafil administration on echocardiography measurements of pulmonary vascular resistance in neonates with Down Syndrome without Congenital Heart Disease.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10067285 Vascular resistance pulmonary increased PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005351-14 Sponsor Protocol Number: CV185-035 Start Date*: 2007-05-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surg...
    Medical condition: Subjects undergoing elective total hip replacement (THR) surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051055 Deep vein thrombosis LLT
    9.1 10037377 Pulmonary embolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed) BE (Completed) GB (Completed) DK (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 22:38:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA